F-Prime's roots are in one of America’s great entrepreneurial success stories. Fidelity Investments was founded in 1946 and grew from a single mutual fund into one of the largest asset management firms in the world, with over $2 trillion in assets under management. For the last forty years, this venture capital group has had the privilege of backing other great entrepreneurs as they built ground-breaking companies in technology and life sciences, including Atari, MCI, ROLM Corp., Alibaba, Ironwood Pharmaceuticals, and Ultragenyx.  Today, F-Prime's funds are larger and more global, but its teams are still small and local. F-Prime stays true to its entrepreneurial roots. In the US and Europe, F-Prime Capital Partners is investing in healthcare (formerly Fidelity Biosciences) and in technology (formerly part of Devonshire Investors). In other geographies, its sister fund is called Eight Roads (formerly Fidelity Growth Partners), with investment teams in London, Shanghai, Beijing, Hong Kong, Tokyo, and Mumbai.   Together F-Prime brings a world of insight, domain expertise and relationships to support entrepreneurs. Without the pressure of fundraising from outside investors, F-Prime Capital Partners focuses all of its time finding and helping great entrepreneurs build important companies.

F-Prime Capital

Omega Funds is a venture capital firm that seeks to invest in the life sciences, digital health, immunology, rare diseases, precision medicine, oncology, cybersecurity, and SaaS sectors.

Omega Funds

Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace. Third Rock Ventures believes in the companies we start and makes significant initial investments, which are frequently supplemented by strategic collaborations, to help our firms progress in life-changing medicines, technologies, and diagnostics.

Third Rock Ventures

ARTBIO

ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines.  ARTBIO is changing cancer care by creating a new class of alpha radioligand therapeutics (ART) and the ecosystem that supports.

ARTBIO is a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs) for cancer treatment. Founded in 2021 by Roy Larsen, Øyvind Bruland, Radforsk, and F-Prime Capital, ARTBIO focuses on creating highly targeted cancer therapies by pairing the alpha-emitting isotope lead-212 (Pb212) with ligands against tumor-specific targets. The company's proprietary AlphaDirect technology enables the isolation of highly pure Pb212 from widely available raw materials. ARTBIO's approach combines Pb212's optimal properties with rationally designed ligands to maximize the therapeutic potential of alpha radioligand therapy. The company's lead program, AB001, is currently in clinical trials for the treatment of prostate cancer. ARTBIO is advancing two additional pipeline programs, aiming to address unmet medical needs in oncology. In December 2023, ARTBIO raised USD 90 million in a Series A financing round to progress its pipeline and isotope technology development. The company is also developing a distributed manufacturing ecosystem to overcome production and distribution challenges associated with the short half-life of Pb212.

ARTBIO Raises Oversubscribed and Upsized $90 Million Series A Financing to Progress Pipeline and Isotope Technology Development for New Class of Alpha Radioligand Therapies

SpectronRx and ARTBIO Join Forces to Develop and Manufacture Clinical Supply of Novel Alpha Radioligand Therapy AB001 for Indiana and Surrounding States

ARTBIO and SpectronRx Enter a Collaboration to Manufacture Key Components of ARTBIO's AlphaDirect™ Technology

ARTBIO and Nucleus RadioPharma Announce Collaboration to Manufacture GMP-Grade Therapeutic Products Containing Radioisotope Pb-212 to Support Emerging Clinical Trials

Radiopharma startup Artbio raises $90M in sign of field’s momentum

ARTBIO, Nucleus RadioPharma Partner to Advance Targeted Alpha Radioligand Therapies for Cancer

ARTBIO and PharmaLogic Announce Supply Agreement for Lead-212 based Therapeutic Candidate AB001 for New York and Surrounding States

FogPharma, Artbio join forces to design a different radiopharma drug

ARTBIO Launches to Develop New Class of Alpha Radioligand Therapies Designed to Maximize Therapeutic Potential

ARTBIO secures $90m to advance ART pipeline

Therapeutics that target specific areas/tissues to minimize treatment side effects.

Tissue Targeting Therapeutics

Oncoinvent Announces Agreement with ARTBIO to Collaborate on Radiopharma Laboratory Facilities

Kharon

To enhance global supply chain security efforts. As part of the collaboration, Exiger’s AI-powered supply chain management platform will be combined with Kharon’s insight into supply chain risk to provide a robust and dynamic risk analysis framework. 

Empowering efficiency, visibility and collaboration throughout supply networks

Supply Chain Tech

Platforms that provide vendor risk intelligence to facilitate vendor due diligence and onboarding, compliance monitoring, contract management, and cybersecurity assessments.

PacBio

Announced a partnership to develop cancer therapies. The financial terms of the agreement have not been disclosed; however, both parties have agreed to contribute equally across all stages from research to commercialization.

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

Biopharma and biotechnology companies that develop precision medicine drugs based on novel disease biomarkers present in multi-omic patient population data and genetic insights.

ARTBIO is a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs) for cancer treatment. Founded in 2021 by Roy Larsen, Øyvind Bruland, Radforsk, and F-Prime Capital, ARTBIO focuses on creating highly targeted cancer therapies by pairing the alpha-emitting isotope lead-212 (Pb212) with ligands against tumor-specific targets. The company's proprietary AlphaDirect technology enables the isolation of highly pure Pb212 from widely available raw materials. ARTBIO's approach combines Pb212's optimal properties with rationally designed ligands to maximize the therapeutic potential of alpha radioligand therapy. The company's lead program, AB001, is currently in clinical trials for the treatment of prostate cancer. ARTBIO is advancing two additional pipeline programs, aiming to address unmet medical needs in oncology. In December 2023, ARTBIO raised USD 90 million in a Series A financing round to progress its pipeline and isotope technology development. The company is also developing a distributed manufacturing ecosystem to overcome production and distribution challenges associated with the short half-life of Pb212.

<div>
 
 Generation Bio is a biotechnology company developing non-viral genetic medicines for rare and prevalent diseases. The company's proprietary platform combines immune-quiet DNA (iqDNA), a novel variant of closed-ended DNA, with a cell-targeted lipid nanoparticle (ctLNP) delivery system and a rapid enzymatic synthesis (RES) manufacturing process. This platform is designed to create gene therapies with drug-like properties, offering durable gene expression, the ability to re-dose for individual patient titration, and the potential to sustain effect over a lifetime. Generation Bio's approach aims to enable multi-year durability from a single dose, deliver large genetic payloads, and allow titration and redosing to adjust or extend expression levels in each patient. The company's pipeline includes programs for liver diseases such as hemophilia A, phenylketonuria (PKU), and Wilson's disease, as well as eye disorders like Stargardt disease and Leber congenital amaurosis type 10. In October 2023, Generation Bio announced the development of iqDNA, which demonstrated cytokine levels and tolerability comparable to chemically modified messenger RNA in mice and non-human primates. Generation Bio's RES manufacturing process has the potential to produce ceDNA at a scale of hundreds of millions of doses.
 
 
 
 
 Key customers and partnerships
 
 
 
 
 In March 2023, Generation Bio entered into a strategic partnership with Moderna to develop non-viral genetic medicines. The collaboration combines Moderna's expertise with Generation Bio's platform technologies to expand their respective non-viral genetic medicines pipelines. Under this partnership, Moderna is using Generation Bio's ctLNP delivery system and iqDNA technology to advance two immune cell programs and two liver programs. The deal included a USD 40 million upfront cash payment and a USD 36 million equity investment from Moderna. Generation Bio will also receive future development, regulatory, and commercial milestone payments, along with royalties on worldwide net sales of immune cell-targeted and liver-targeted products. The partnership aims to develop new lipid nanoparticles and expand in vivo immune cell targeting as a new class of genetic medicines.
 
</div>

Generation Bio

Oncopeptides AB is a biotech company focused on developing therapies for difficult-to-treat hematological diseases, particularly multiple myeloma. The company's lead product, PEPAXTO (melphalan flufenamide, also known as melflufen), received FDA approval in February 2021 for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy. PEPAXTO is the first anticancer peptide-drug conjugate approved by the FDA for this indication. The drug works by leveraging aminopeptidases, which are overexpressed in multiple myeloma cells, to release cytotoxic agents.
In August 2022, the European Commission granted marketing authorization for Pepaxti (melphalan flufenamide) in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies. Oncopeptides' research is based on two technology platforms: Peptide Drug Conjugates (PDC) and Small Polypeptide based Innate Killer Engagers (SPiKE). The PDC platform allows for efficient drug distribution in the body, enabling a wide therapeutic window and an optimized benefit-risk profile. The SPiKE platform utilizes the immune system to fight cancer by targeting natural killer cells, potentially reducing dose-limiting side effects while maintaining clinical efficacy.
As of 2023, Oncopeptides was conducting one clinical phase 3 study and six clinical phase 2 studies. The company's pipeline includes innovative drug candidates for difficult-to-treat hematological diseases, with the potential to expand into new indications. Oncopeptides' approach is science and data-driven, focusing on bringing innovation to patients with rare hematological diseases.

Oncopeptides

Neurona Therapeutics is a clinical-stage biotherapeutics company focused on developing regenerative cell therapy candidates for the treatment of neurological disorders. The company's lead investigational candidate, NRTX-1001, is being evaluated in an ongoing Phase I/II clinical trial for drug-resistant mesial temporal lobe epilepsy (MTLE). NRTX-1001 is a regenerative neural cell therapy derived from human pluripotent stem cells. It consists of fully-differentiated neural cells called interneurons that secrete the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). Delivered as a one-time dose, these human interneurons are intended to integrate on-target and durably silence seizure activity in the epileptic region of the brain. In December 2023, Neurona presented early data from five participants in the ongoing study of NRTX-1001. Two patients who received the therapy more than a year prior experienced at least a 95% reduction in overall seizure frequency. NRTX-1001 is manufactured in Neurona's in-house GMP facility using proprietary methods. Beyond epilepsy, Neurona is also evaluating NRTX-1001 for potential application in Alzheimer's disease. The company's pipeline includes other cell therapy candidates such as investigational myelinating glial cells and gene-edited cells for undisclosed indications.

Neurona Therapeutics

Evox Therapeutics is a biotechnology company specializing in exosome therapeutics. The company utilizes its proprietary DeliverEX technology to engineer exosomes for drug delivery to specific organs, including the brain and central nervous system. Evox's approach aims to overcome limitations of genetic medicines such as gene therapy, gene editing, and RNA therapeutics by enabling safe, non-immunogenic repeated delivery to cells and tissues that are challenging to reach with other drug delivery technologies.
The company's technology focuses on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop a new class of therapeutics for treating severe rare diseases. Evox's intellectual property portfolio includes more than 100 granted patents across key jurisdictions, covering various aspects of exosome-based drug design, development, and manufacturing. In May 2023, Evox was granted a US patent for a method of purifying engineered exosomes using ultrafiltration and size-based separation steps, which is widely used in exosome therapeutics.
In June 2023, Evox acquired Codiak Biosciences' engEx-AAV technology platform, which enables active loading of adeno-associated virus (AAV) into exosomes. This technology has demonstrated improved AAV delivery, increased expression breadth in preclinical models, and shielding of AAVs from neutralizing antibodies. The acquisition aligns with Evox's strategy to enhance exosome-mediated delivery for genetic medicines such as gene therapy and genome editors.

Evox Therapeutics

Aro Biotherapeutics is a clinical-stage biotechnology company based in Philadelphia that specializes in developing tissue-targeted genetic medicines. The company's core technology is a proprietary protein platform called Centyrins, which enables efficient and tissue-specific delivery of siRNA and other genetic drugs. Aro's lead candidate, ABX1100, is being developed for the treatment of Pompe disease, a rare genetic disorder characterized by toxic glycogen accumulation in muscles. ABX1100 comprises a CD71 receptor-binding Centyrin conjugated to a small interfering RNA (siRNA) that targets the Gys1 gene, reducing levels and activity of the Gys1 enzyme in muscle tissues. The therapy has shown promising results in preclinical studies, demonstrating potent and muscle-specific reductions in Gys1 mRNA and protein in the Pompe mouse model. In October 2023, Aro initiated a Phase 1 clinical trial of ABX1100 in Canada, with initial data expected in 2024. The US Food and Drug Administration granted ABX1100 Orphan Drug Designation and Rare Pediatric Disease status. Beyond Pompe disease, Aro is exploring the potential of its Centyrin-siRNA conjugate programs for developing new treatments for autoimmune disorders.

Aro Biotherapeutics

Therapeutics that are designed to target specific cells to reach designated target sites

Therapeutics that are designed to target specific protein or protein receptors to reach designated target sites

Therapeutics that use different targeting approaches, such as bone-targeting or pressure-based, to help therapeutics identify specific target sites

Companies that offer contract research and manufacturing facilities that focus on tissue-targeting therapeutics for life sciences organizations

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

PROMINENT_CATEGORY

<div>
 Boston-based biotechnology company FogPharma and radiopharmaceuticals company ARTBIO have entered into a collaboration to develop novel cancer therapies. With financial terms remaining undisclosed, both firms agreed to have equal contributions in all stages from research to commercialization.&nbsp;
 This partnership will exploit the peptide capabilities of FogPharma’s Helicon platform and the AlphaDirect platform of ARTBIO for radioligand therapies. Together, they intend to develop Helicon-Enhanced Alpha Radioligand Therapeutics (HEARTs) for various forms of cancer.&nbsp;
 FogPharma, located in Massachusetts, is on a mission to discover and develop a new class of precision medicines, Helicon Therapeutics. These peptides have the potential to infiltrate cells and regulate protein/DNA interactions. Through this capability, FogPharma aims to target intracellular mechanisms known to play crucial roles in disease progression.
</div>

ARTBIO

Sources

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless